{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:54:46Z","timestamp":1790924086973,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017067","name":"Sbarro Health Research Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017067","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Bladder cancer (BC) is one of the most deadly diseases in the USA, with 84,530 new cases and 17,870 estimated deaths in 2026. The growth factor progranulin is involved in several human pathologies, including frontotemporal dementia (FTD), immune response, and cancer. We showed that in BC, progranulin and its signaling receptor, EphA2, drive tumor cell motility, invasion, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      tumor formation, making it a critical pathway in tumor establishment. However, the molecular mechanisms of progranulin\/EphA2 action are still poorly defined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Progranulin-dependent EphA2 interactome was explored by proteomic approaches. FAM120A or EphA2 protein levels in BC tissue microarrays (TMAs) and FAM120A protein expression in BC cell lines were analyzed by immunohistochemistry (IHC) and immunoblots, respectively. Progranulin-dependent activation of AKT and ERK1\/2 were examined by western immunoblots. EphA2-FAM120A interaction was detected using Co-immunoprecipitation and proximity ligation assays (PLA). In addition, EphA2 and FAM120A colocalization and F-actin cytoskeleton rearrangements were assessed by immunofluorescence. The biological function of FAM120A was determined using lentiviral shRNA approaches, wound healing, motility and invasion, spheroid, soft agar, clonogenic assays, cell cytotoxicity, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      xenograft models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      We conducted proteomic approaches and identified novel progranulin-dependent EphA2 interactors, including FAM120A, which is a scaffold protein with a putative role in oncogenic pathways. We confirmed that the EphA2 and FAM120A interaction was enhanced upon progranulin stimulation, and FAM120A was upregulated in BC tissues. We further demonstrated that FAM120A was critical for progranulin-evoked AKT and ERK1\/2 activation, clonogenic capacity, wound healing, motility, invasion, and 3D spheroid formation of BC cell lines. In addition, FAM120A was essential for anchorage-independent growth and\n                      <jats:italic>in vivo<\/jats:italic>\n                      tumorigenesis in xenograft models. In addition, FAM120A depletion sensitized BC cells to cisplatin treatment. Mechanistically, we showed that FAM120A depletion inhibited progranulin-dependent F-actin cytoskeleton rearrangement through ERK1\/2 and RhoA-dependent pathways. Furthermore, we demonstrated that progranulin-induced activation of RhoA was inhibited upon FAM120A depletion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The discovery of FAM120A as an oncogenic progranulin-dependent EphA2 interactor provides novel insights into the progranulin\/EphA2 signaling axis and uncovers putative novel targets for BC therapy. Furthermore, FAM120A expression may work as a biomarker with diagnostic and possibly prognostic value in BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03808-1","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:43:47Z","timestamp":1786452227000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional characterization of FAM120A as a novel effector in the progranulin\/EphA2 oncogenic axis in bladder cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Vrunda","family":"Satasiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pascal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Raffaella","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Nana","family":"Tchamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shendi","family":"Shani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato V.","family":"Iozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-7884","authenticated-orcid":false,"given":"Andrea","family":"Morrione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"1","key":"3808_CR1","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3808_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","volume":"24","author":"M Mossanen","year":"2014","unstructured":"Mossanen M, Gore JL. The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol. 2014;24(5):487\u201391.","journal-title":"Curr Opin Urol"},{"key":"3808_CR3","doi-asserted-by":"publisher","unstructured":"Ventura E, Ducci G, Benot Dominguez R, Ruggiero V, Belfiore A, Sacco E, Vanoni M, Iozzo RV, Giordano A, Morrione A. Progranulin oncogenic network in solid tumors. Cancers (Basel). 2023;15(6):1706. https:\/\/doi.org\/10.3390\/cancers15061706.\u00a0PMID: 36980592; PMCID:PMC10046331.","DOI":"10.3390\/cancers15061706"},{"issue":"1","key":"3808_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-023-00327-0","volume":"20","author":"A Saeedi-Boroujeni","year":"2023","unstructured":"Saeedi-Boroujeni A, et al. Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases. J Inflamm (Lond). 2023;20(1):1.","journal-title":"J Inflamm (Lond)"},{"key":"3808_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107957","volume":"221","author":"S Salzano","year":"2025","unstructured":"Salzano S, et al. Frontotemporal dementia as a consequence of GRN mutations: from disease cause to models to therapies. Pharmacol Res. 2025;221:107957.","journal-title":"Pharmacol Res"},{"issue":"4","key":"3808_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1110\/ps.073295308","volume":"17","author":"D Tolkatchev","year":"2008","unstructured":"Tolkatchev D, et al. Structure dissection of human progranulin identifies well-folded granulin\/epithelin modules with unique functional activities. Protein Sci. 2008;17(4):711\u201324.","journal-title":"Protein Sci"},{"issue":"7","key":"3808_CR7","first-page":"2438","volume":"118","author":"K Kessenbrock","year":"2008","unstructured":"Kessenbrock K, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 2008;118(7):2438\u201347.","journal-title":"J Clin Invest"},{"issue":"7","key":"3808_CR8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/art.27491","volume":"62","author":"F Guo","year":"2010","unstructured":"Guo F, et al. Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum. 2010;62(7):2023\u201336.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3808_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12032-017-1054-7","volume":"34","author":"F Arechavaleta-Velasco","year":"2017","unstructured":"Arechavaleta-Velasco F, et al. Progranulin and its biological effects in cancer. Med Oncol. 2017;34(12):194.","journal-title":"Med Oncol"},{"issue":"8","key":"3808_CR10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.tips.2021.11.015","volume":"43","author":"H Rhinn","year":"2022","unstructured":"Rhinn H, et al. Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol Sci. 2022;43(8):641\u201352.","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"3808_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114985","volume":"43","author":"J Root","year":"2024","unstructured":"Root J, et al. Granulins rescue inflammation, lysosome dysfunction, lipofuscin, and neuropathology in a mouse model of progranulin deficiency. Cell Rep. 2024;43(12):114985.","journal-title":"Cell Rep"},{"issue":"14","key":"3808_CR12","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1158\/0008-5472.CAN-06-0633","volume":"66","author":"G Monami","year":"2006","unstructured":"Monami G, et al. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1\/2 and the formation of a paxillin\/FAK\/ERK complex. Cancer Res. 2006;66(14):7103\u201310.","journal-title":"Cancer Res"},{"issue":"5","key":"3808_CR13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/carcin\/bgp050","volume":"30","author":"F Lovat","year":"2009","unstructured":"Lovat F, et al. Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis. 2009;30(5):861\u20138.","journal-title":"Carcinogenesis"},{"issue":"13","key":"3808_CR14","doi-asserted-by":"crossref","first-page":"10825","DOI":"10.18632\/oncotarget.3424","volume":"6","author":"SQ Xu","year":"2015","unstructured":"Xu SQ, et al. A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget. 2015;6(13):10825\u201339.","journal-title":"Oncotarget"},{"issue":"26","key":"3808_CR15","doi-asserted-by":"crossref","first-page":"39980","DOI":"10.18632\/oncotarget.9556","volume":"7","author":"S Buraschi","year":"2016","unstructured":"Buraschi S, et al. Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget. 2016;7(26):39980\u201395.","journal-title":"Oncotarget"},{"issue":"3","key":"3808_CR16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2353\/ajpath.2009.080735","volume":"174","author":"G Monami","year":"2009","unstructured":"Monami G, et al. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol. 2009;174(3):1037\u201347.","journal-title":"Am J Pathol"},{"issue":"1","key":"3808_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13046-022-02546-4","volume":"41","author":"E Ventura","year":"2022","unstructured":"Ventura E, et al. Complexity of progranulin mechanisms of action in mesothelioma. J Exp Clin Cancer Res. 2022;41(1):333.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"3808_CR18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.201603079","volume":"215","author":"T Neill","year":"2016","unstructured":"Neill T, et al. EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol. 2016;215(5):687\u2013703.","journal-title":"J Cell Biol"},{"key":"3808_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.matbio.2020.03.009","volume":"93","author":"S Buraschi","year":"2020","unstructured":"Buraschi S, et al. Progranulin\/EphA2 axis: a novel oncogenic mechanism in bladder cancer. Matrix Biol. 2020;93:10\u201324.","journal-title":"Matrix Biol"},{"key":"3808_CR20","doi-asserted-by":"publisher","unstructured":"Hayai S, Suzuki MM, Iijima K, Shinjo K, Murofushi Y, Xie J, Nishimura T, Ishii M, Kondo Y. A stress granule-associated RNA-binding protein FAM120A drives cisplatin resistance in non-small cell lung cancer. J Biochem. 2025;179(2):127\u201335. https:\/\/doi.org\/10.1093\/jb\/mvaf074.\u00a0PMID: 41328536; PMCID: PMC12866663.","DOI":"10.1093\/jb\/mvaf074"},{"issue":"16","key":"3808_CR21","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.molcel.2023.07.017","volume":"83","author":"S Cho","year":"2023","unstructured":"Cho S, et al. FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1. Mol Cell. 2023;83(16):3010-3026 e8.","journal-title":"Mol Cell"},{"issue":"12","key":"3808_CR22","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1158\/0008-5472.CAN-14-3650","volume":"75","author":"RA Bartolome","year":"2015","unstructured":"Bartolome RA, et al. IL13 Receptor alpha2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res. 2015;75(12):2434\u201344.","journal-title":"Cancer Res"},{"issue":"40","key":"3808_CR23","doi-asserted-by":"crossref","first-page":"38113","DOI":"10.1074\/jbc.C300310200","volume":"278","author":"EM Gonzalez","year":"2003","unstructured":"Gonzalez EM, et al. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem. 2003;278(40):38113\u20136.","journal-title":"J Biol Chem"},{"issue":"35","key":"3808_CR24","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1038\/sj.onc.1204649","volume":"20","author":"A Morrione","year":"2001","unstructured":"Morrione A, et al. The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells. Oncogene. 2001;20(35):4842\u201352.","journal-title":"Oncogene"},{"issue":"8","key":"3808_CR25","first-page":"2263","volume":"60","author":"A Morrione","year":"2000","unstructured":"Morrione A, et al. Insulin-like growth factor I receptor signaling in differentiation of neuronal H19\u20137 cells. Cancer Res. 2000;60(8):2263\u201372.","journal-title":"Cancer Res"},{"key":"3808_CR26","doi-asserted-by":"crossref","unstructured":"Campioni, G., et al., An Optimized Workflow for the Analysis of Metabolic Fluxes in Cancer Spheroids Using Seahorse Technology. Cells. 2022;11(5).","DOI":"10.3390\/cells11050866"},{"key":"3808_CR27","doi-asserted-by":"publisher","unstructured":"Toracchio L, Carrabotta M, Mancarella C, Morrione A, Scotlandi K. EphA2 in cancer: molecular complexity and therapeutic opportunities. Int J Mol Sci. 2024;25(22):12191. https:\/\/doi.org\/10.3390\/ijms252212191.\u00a0PMID: 39596256; PMCID:PMC11594831.","DOI":"10.3390\/ijms252212191"},{"issue":"10","key":"3808_CR28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1261\/rna.071621.119","volume":"25","author":"TJ Kelly","year":"2019","unstructured":"Kelly TJ, et al. Sequestration of microRNA-mediated target repression by the Ago2-associated RNA-binding protein FAM120A. RNA. 2019;25(10):1291\u20137.","journal-title":"RNA"},{"issue":"1","key":"3808_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s42003-024-06097-6","volume":"7","author":"L Niu","year":"2024","unstructured":"Niu L, et al. FAM120A deficiency improves resistance to cisplatin in gastric cancer by promoting ferroptosis. Commun Biol. 2024;7(1):399.","journal-title":"Commun Biol"},{"issue":"D1","key":"3808_CR30","doi-asserted-by":"crossref","first-page":"D1246","DOI":"10.1093\/nar\/gkad1060","volume":"52","author":"CH Liu","year":"2024","unstructured":"Liu CH, et al. DriverDBv4: a multi-omics integration database for cancer driver gene research. Nucleic Acids Res. 2024;52(D1):D1246\u201352.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3808_CR31","volume":"123","author":"MS Alam","year":"2018","unstructured":"Alam MS. Proximity ligation assay (PLA). Curr Protoc Immunol. 2018;123(1):e58.","journal-title":"Curr Protoc Immunol"},{"key":"3808_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4939-8559-3_9","volume":"1806","author":"SQ Xu","year":"2018","unstructured":"Xu SQ, et al. Analysis of progranulin-mediated Akt and MAPK activation. Methods Mol Biol. 2018;1806:121\u201330.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3808_CR33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/en.2014-1590","volume":"156","author":"R Tanimoto","year":"2015","unstructured":"Tanimoto R, et al. Sortilin regulates progranulin action in castration-resistant prostate cancer cells. Endocrinology. 2015;156(1):58\u201370.","journal-title":"Endocrinology"},{"key":"3808_CR34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fendo.2016.00100","volume":"7","author":"R Tanimoto","year":"2016","unstructured":"Tanimoto R, et al. Mechanisms of progranulin action and regulation in genitourinary cancers. Front Endocrinol (Lausanne). 2016;7:100.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3808_CR35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.18632\/oncotarget.28657","volume":"15","author":"S Buraschi","year":"2024","unstructured":"Buraschi S, et al. Correction: suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget. 2024;15:697\u20138.","journal-title":"Oncotarget"},{"issue":"2","key":"3808_CR36","doi-asserted-by":"crossref","first-page":"C391","DOI":"10.1152\/ajpcell.00248.2023","volume":"325","author":"E Ventura","year":"2023","unstructured":"Ventura E, et al. Progranulin and EGFR modulate receptor-like tyrosine kinase sorting and stability in mesothelioma cells. Am J Physiol Cell Physiol. 2023;325(2):C391\u2013405.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3808_CR37","doi-asserted-by":"publisher","unstructured":"Aseervatham J. Cytoskeletal remodeling in cancer. Biology (Basel). 2020;9(11):385. https:\/\/doi.org\/10.3390\/biology9110385.\u00a0PMID:33171868; PMCID: PMC7695181.","DOI":"10.3390\/biology9110385"},{"issue":"2","key":"3808_CR38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4161\/cam.5.2.15257","volume":"5","author":"K Sobue","year":"2011","unstructured":"Sobue K. The actin cytoskeleton as a pivotal molecular basis for cell motility: letter from the guest editor. Cell Adh Migr. 2011;5(2):142\u20133.","journal-title":"Cell Adh Migr"},{"issue":"14","key":"3808_CR39","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1073\/pnas.85.14.5107","volume":"85","author":"DR Senger","year":"1988","unstructured":"Senger DR, Perruzzi CA, Ali IU. T24 human bladder carcinoma cells with activated Ha-ras protooncogene: nontumorigenic cells susceptible to malignant transformation with carcinogen. Proc Natl Acad Sci U S A. 1988;85(14):5107\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3808_CR40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9","volume":"27","author":"JJ Gildea","year":"2000","unstructured":"Gildea JJ, et al. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer. 2000;27(3):252\u201363.","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"3808_CR41","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"3808_CR42","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","volume":"119","author":"K Chamie","year":"2013","unstructured":"Chamie K, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219\u201327.","journal-title":"Cancer"},{"key":"3808_CR43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2022.07.008","volume":"69","author":"M Vliora","year":"2023","unstructured":"Vliora M, et al. The impact of adipokines on vascular networks in adipose tissue. Cytokine Growth Factor Rev. 2023;69:61\u201372.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"3808_CR44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rbmo.2022.11.006","volume":"46","author":"R Qin","year":"2023","unstructured":"Qin R, et al. Progranulin promotes proliferation, migration and invasion via the PI3K\/Akt signalling pathway in a model of endometriosis. Reprod Biomed Online. 2023;46(3):425\u201335.","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"3808_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05849","volume":"7","author":"K Yabe","year":"2021","unstructured":"Yabe K, et al. Progranulin depletion inhibits proliferation via the transforming growth factor beta\/SMAD family member 2 signaling axis in Kasumi-1 cells. Heliyon. 2021;7(1):e05849.","journal-title":"Heliyon"},{"key":"3808_CR46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/978-3-030-73119-9_22","volume":"1329","author":"G Serrero","year":"2021","unstructured":"Serrero G. Progranulin\/GP88, a complex and multifaceted player of tumor growth by direct action and via the tumor microenvironment. Adv Exp Med Biol. 2021;1329:475\u201398.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"3808_CR47","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.70188","volume":"241","author":"G Insinga","year":"2026","unstructured":"Insinga G, et al. Progranulin and inflammation-induced cancer: an important player in the tumor microenvironment? J Cell Physiol. 2026;241(5):e70188.","journal-title":"J Cell Physiol"},{"issue":"2","key":"3808_CR48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/MCB.01035-08","volume":"29","author":"M Tanaka","year":"2009","unstructured":"Tanaka M, et al. A novel RNA-binding protein, Ossa\/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol. 2009;29(2):402\u201313.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"3808_CR49","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1541-7786.MCR-08-0244","volume":"6","author":"J Wykosky","year":"2008","unstructured":"Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008;6(12):1795\u2013806.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"3808_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","volume":"10","author":"EB Pasquale","year":"2010","unstructured":"Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"52","key":"3808_CR51","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1038\/sj.onc.1204004","volume":"19","author":"K Ogawa","year":"2000","unstructured":"Ogawa K, et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000;19(52):6043\u201352.","journal-title":"Oncogene"},{"issue":"12","key":"3808_CR52","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/tra.12123","volume":"14","author":"P Boissier","year":"2013","unstructured":"Boissier P, Chen J, Huynh-Do U. EphA2 signaling following endocytosis: role of Tiam1. Traffic. 2013;14(12):1255\u201371.","journal-title":"Traffic"},{"issue":"1","key":"3808_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","volume":"24","author":"EB Pasquale","year":"2024","unstructured":"Pasquale EB. Eph receptors and ephrins in cancer progression. Nat Rev Cancer. 2024;24(1):5\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3808_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"1","key":"3808_CR55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3808_CR56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"3808_CR57","doi-asserted-by":"crossref","first-page":"607","DOI":"10.29271\/jcpsp.2018.08.607","volume":"28","author":"J Zhao","year":"2018","unstructured":"Zhao J, et al. Effect of progranulin on migration and invasion of human colon cancer cells. J Coll Physicians Surg Pak. 2018;28(8):607\u201311.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"3","key":"3808_CR58","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10549-021-06120-y","volume":"186","author":"R Guha","year":"2021","unstructured":"Guha R, et al. Anti-progranulin\/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. Breast Cancer Res Treat. 2021;186(3):637\u201353.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3808_CR59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-15-0603","volume":"22","author":"PD Dunne","year":"2016","unstructured":"Dunne PD, et al. EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clin Cancer Res. 2016;22(1):230\u201342.","journal-title":"Clin Cancer Res"},{"key":"3808_CR60","doi-asserted-by":"publisher","unstructured":"Yang C, Wang S, Li M, Pang X, Tan A. Targeting EphA2 suppresses the proliferation, migration and invasion ofendometriosis via the AMPK signaling pathway. Eur J Histochem. 2025;69(3):4168. https:\/\/doi.org\/10.4081\/ejh.2025.4168.\u00a0Epub 2025 Jun 17. PMID:40525819; PMCID: PMC12210881.","DOI":"10.4081\/ejh.2025.4168"},{"issue":"1","key":"3808_CR61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","volume":"16","author":"H Miao","year":"2009","unstructured":"Miao H, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009;16(1):9\u201320.","journal-title":"Cancer Cell"},{"key":"3808_CR62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cytogfr.2024.09.002","volume":"80","author":"C Liu","year":"2024","unstructured":"Liu C, et al. Mechanisms of Rho GTPases in regulating tumor proliferation, migration and invasion. Cytokine Growth Factor Rev. 2024;80:168\u201374.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"3808_CR63","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1038\/s41467-025-64635-0","volume":"16","author":"H Lee","year":"2025","unstructured":"Lee H, et al. A Rho GTPase-effector ensemble governs cell migration behavior. Nat Commun. 2025;16(1):9637.","journal-title":"Nat Commun"},{"issue":"22","key":"3808_CR64","first-page":"7907","volume":"63","author":"KT Coffman","year":"2003","unstructured":"Coffman KT, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003;63(22):7907\u201312.","journal-title":"Cancer Res"},{"issue":"22","key":"3808_CR65","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-08-1933","volume":"68","author":"D Jackson","year":"2008","unstructured":"Jackson D, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008;68(22):9367\u201374.","journal-title":"Cancer Res"},{"key":"3808_CR66","doi-asserted-by":"publisher","unstructured":"Bennett G, Riedl J, Mudd G. Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates. J Transl Med. 2026;24(1):322. https:\/\/doi.org\/10.1186\/s12967-026-07870-3.\u00a0PMID: 41782030; PMCID: PMC12961899.","DOI":"10.1186\/s12967-026-07870-3"},{"issue":"9","key":"3808_CR67","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai JM, et al. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol. 2024;25(9):740\u201357.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3808_CR68","doi-asserted-by":"publisher","unstructured":"Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- andVemurafenib-Resistant Melanoma. Pharmaceutics. 2019;11(10):504. https:\/\/doi.org\/10.3390\/pharmaceutics11100504.\u00a0PMID: 31581483; PMCID:PMC6836218.","DOI":"10.3390\/pharmaceutics11100504"},{"key":"3808_CR69","volume":"11","author":"Q Lin","year":"2021","unstructured":"Lin Q, et al. First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose. Front Oncol. 2021;11:694941.","journal-title":"Front Oncol"},{"issue":"16_Suppl","key":"3808_CR70","first-page":"Tps2669","volume":"44","author":"KHR Tkaczuk","year":"2026","unstructured":"Tkaczuk KHR, et al. Phase 1 first-in-human trial of AG01, a recombinant humanized monoclonal antibody to progranulin\/glycoprotein 88 (GP88) to determine the safety, tolerability, pharmacokinetics, and preliminary antitumor activity in subjects with advanced solid tumor malignancies. J Clin Oncol. 2026;44(16_Suppl):Tps2669\u2013Tps2669.","journal-title":"J Clin Oncol"},{"key":"3808_CR71","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.586107","volume":"14","author":"S Miyakawa","year":"2020","unstructured":"Miyakawa S, et al. Anti-sortilin1 antibody up-regulates progranulin via sortilin1 down-regulation. Front Neurosci. 2020;14:586107.","journal-title":"Front Neurosci"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03808-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03808-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03808-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:32:55Z","timestamp":1790922775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03808-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3808"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03808-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In vivo\n                      experiments were performed according to protocols approved by the Institutional Review Board of Thomas Jefferson University.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"205"}}